Around 70% of breast cancers are estrogen receptor (ER) positive, and therefore can be treated with endocrine therapy (2), which exerts anti-tumor activity by depriving cancer cells of growth stimulating hormones. This evidence concerns the gene ESR1 and breast carcinoma.